Search

Search Constraints

You searched for: Author/Creator Gee, Michelle

Search Results

1. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021)

2. Bioengineered 3D Tissue Model of Intestine Epithelium with Oxygen Gradients to Sustain Human Gut Microbiome. Issue 16 (19th June 2022)

3. Diversity in Phase 2 and Phase 3 Placebo‐Controlled, Double‐Blind, Lecanemab and Elenbecestat Early Alzheimer's Disease Studies. (20th December 2022)

4. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach. (June 2014)

5. Initial exploration of a brain age score based on validated computerized cognitive assessments in Japanese individuals: Neuropsychology/Multicultural issues in assessment of dementia. (7th December 2020)

7. Lead Discovery for Human Kynurenine 3-Monooxygenase by High-Throughput RapidFire Mass Spectrometry. (April 2014)

8. LONG-TERM SAFETY OF PERAMPANEL: ADDITIONAL 10 MONTHS OF DATA FROM EXTENSION STUDY 307 IN PATIENTS WITH PARTIAL-ONSET SEIZURES AGED 12 AND ABOVE. Issue 10 (9th September 2014)

10. Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Issue 7 (27th May 2014)